

BRIAN SANDOVAL
Governor



RICHARD WHITLEY, MS
Director

MARTA JENSEN
Administrator

DEPARTMENT OF HEALTH AND HUMAN SERVICES
DIVISION OF HEALTH CARE FINANCING AND POLICY
1100 East William Street, Suite 101
Carson City, Nevada 89701
Telephone (775) 684-3676 • Fax (775) 687-3893
<http://dhcfp.nv.gov>

NOTICE OF PUBLIC MEETING – PHARMACY AND THERAPEUTICS COMMITTEE

AGENDA

Date of Publication: October 9, 2018

Date and Time of Meeting: November 15, 2018 at 1:00 PM

Name of Organization: The State of Nevada, Department of Health and Human Services (DHHS), Division of Health Care Financing and Policy (DHCFP)

Place of Meeting: Springs Preserve
333 S. Valley View Blvd.
Las Vegas, Nevada 89107

Webinar Registration: <https://optum.webex.com/optum/onstage/g.php?MTID=ea21c16cb9329f314d59a9b7bb1d3a322>

OR

www.webex.com, select “Join,” enter Meeting Number 649 127 642, your name and email and then select, “Join.”

A Password should not be necessary, but if asked, enter “Medicaid1!”

OR

Audio Only: (763) 957-6300

Event Number: 649 127 642

Follow the instructions that appear on your screen to join the teleconference. Audio will also be broadcast over the internet (VoIP).

Reasonable efforts will be made to assist and accommodate physically challenged persons desiring to attend the meeting. Please call Wendy Montgomery at: (775) 684-3722 or email wmontgomery@dhefp.nv.gov in advance, but no later than two working days prior to the meeting, so that arrangements may be conveniently made.

Items may be taken out of order.

Items may be combined for consideration by the public body.

Items may be pulled or removed from the agenda at any time.

Public comment is limited to five minutes per individual, organization, or agency, but may be extended at the discretion of the Chairperson.

AGENDA

1. **Call to Order and Roll Call**
2. **Public Comment**
3. **Administrative**
 - a. **For Possible Action:** Review and Approve Meeting Minutes from September 27, 2018
 - b. Status Update by the DHEFP
 1. Public Comment
4. **Established Drug Classes Being Reviewed Due to the Release of New Drugs**
 - a. Neurological Agents – Anticonvulsants
 1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by OptumRx and the DHEFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
 - b. Toxicology Agents - Substance Abuse Agents - Mixed Opiate Agonists/Antagonists
 1. Public Comment
 2. Drug Class Review Presentation – OptumRx

3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

5. Established Drug Classes

- a. Biologic Response Modifiers - Multiple Sclerosis Agents - Specific Symptomatic Treatment
 1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- b. Neurological Agents - Anticonvulsants - Benzodiazepines
 1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- c. Psychotropic Agents - ADHD Agents
 1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP

5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
6. **Report by OptumRx on New Drugs to Market, New Generic Drugs to Market and New Line Extensions**
7. **Closing Discussion**
 - a. Public comments on any subject
 - b. Date and location of the next meeting
 - c. Adjournment

Items may be taken out of order. Two or more agenda items may be combined for consideration. Items may be removed from the agenda or discussion of items may be delayed at any time.

Notice of this public workshop meeting and draft copies of the changes will be available on or after the date of this notice at the DHCFP Web site at <http://dhcfnv.gov>. The agenda posting of this meeting can be viewed at the follow locations: Carson City Central Office; Las Vegas District Office; Reno District Office; Elko District Office; Nevada State Library; Carson City Library; Churchill County Library; Las Vegas Library; Douglas County Library; Elko County Library; Esmeralda County Library; Lincoln County Library; Lyon County Library; Mineral County Library; Tonopah Public Library; Pershing County Library; Goldfield Public Library; Eureka Branch Library; Humboldt County Library; Lander County Library; Storey County Library; Washoe County Library; and White Pine County Library and may be reviewed during normal business hours.

If requested in writing, a copy of the proposal will be mailed to you. Requests and/or written comments on the proposed changes may be sent to the Division of Health Care Financing and Policy, 1100 E. William Street, Suite 101, Carson City, Nevada 89701 at least three days' prior the public workshop.

All persons that have requested in writing to receive the Public Workshop Agenda have been duly notified by mail or e-mail.

Note: We are pleased to make reasonable accommodations for members of the public who are physically challenged and wish to attend the meeting. If special arrangements for the meeting are necessary, please notify the Division of Health Care Financing and Policy, in writing, at 1100 East William Street, Suite 101, Carson City, or call Wendy Montgomery at (775) 684-3722, as soon as possible, or e-mail at wmontgomery@dhcfnv.gov
